P-28 Urine IP-10 as a biomarker for monitoring the progression of treatment in patients with active pulmonary TB = P-28 Urine IP-10 as a biomarker for monitoring the progression of treatment in patients with active pulmonary TB

다국어 초록 (Multilingual Abstract)

Tuberculosis (TB) remains a major infectious cause of mortality and morbidity, with approximately 8.6 million new cases and 1.3 million deaths per every year (WHO 2015). Innovative efforts have been made to meet the global targets on tuberculosis control. In order to evaluate novel development on vaccines and drugs, it is essential to have effective surrogate markers of risk and protection against TB in advance. Especially in preparation of clinical trials on new TB drugs or therapeutic vaccines, monitoring tools should be ready to predict the progression outcomes of treatment in TB patients. Culture conversion at 2 months of drug treatment has been used as a predictive index for drug treatment response in patients. However, the result of culture is not always available in a resource-limited setting. Interferon-γ-induced protein 10 kDa (IP-10) is a pro-inflammatory chemokine produced by monocytes and macrophages that traffics Th1 lymphocytes to inflamed foci. Previous studies showed that measurement of IP-10 in urine can be useful to monitor the progress of treatment. In this study, we evaluated the level of IP-10 in a serial urine samples from patients with active TB. The data showed that levels of IP-10 in urine significantly increased after 2-month of treatment but decreased by the completion of treatment (P < 0.01). In conclusion, unstimulated IP-10 in urine of patients can be used to monitor the progression of treatment in TB patients.